Medical News

RSS

Negative health impacts caused by 'forever chemicals' linked to billions in economic losses

The negative health impacts from contamination by so called "forever chemicals" in drinking water costs the contiguous U.S. at least $8 billion a year in social costs, a University of Arizona-led study has found.

9 Dec 2025

Research ushers in a new era of hope for patients with primary immune thrombocytopenia

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune disorder that can cause life-threatening bleeding, were able to maintain safe platelet counts without serious bleeding episodes for at least one year.

9 Dec 2025

Disinfectant used in water treatment may impact the incidence of Legionnaire's disease

Preliminary results of a nationwide study suggest that the disinfectant used to treat water before it is distributed through pipes may impact the incidence of Legionnaire's disease in certain parts of the country.

9 Dec 2025

Brain function discovery helps explain why childhood adversity raises metabolic disease risk in women

McGill University researchers have identified a brain function that helps explain why childhood stress raises metabolic health risks for some women later in life.

9 Dec 2025

Study uncovers how the body's bile acids bind to block C. diff's most dangerous toxin

In a major step towards a precision therapy for Clostridioides difficile (C. diff) infection, researchers at The Hospital for Sick Children (SickKids) have uncovered how the body's bile acids bind to block C. diff's most dangerous toxin.

9 Dec 2025

Dietary restriction reprograms cancer-fighting immune cells to enhance anti-tumour immunity

Reducing calorie intake helps cancer-fighting immune cells do their jobs more effectively, reports a study by Van Andel Institute scientists and collaborators.

9 Dec 2025

TXA reduces the need for blood transfusion in patients undergoing high-risk non-cardiac surgery

When hospitals were randomly assigned to treat patients undergoing higher-risk non-cardiac surgery with tranexamic acid (TXA) or a placebo, patients who received TXA needed significantly fewer blood transfusions and saw no increase in potentially life-threatening blood clots (thrombosis) after 90 days of follow-up, according to research presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

9 Dec 2025

New study could lead to quicker and more targeted support for vulvodyniaia

A first-of-its-kind University of Stirling-led study could lead to quicker and more targeted support for vulvodynia - a painful chronic condition estimated to affect more than one in 10 women with no known cause.

9 Dec 2025

Most people wary of AI for health diagnosis but optimistic for cancer detection

New research on public attitudes toward AI indicates that most people are reluctant to let ChatGPT and other AI tools diagnose their health condition, but see promise in technologies that use AI to help diagnose cancer.

9 Dec 2025

Highly sensitive CRISPR-based method designed to detect low-frequency cancer mutations

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its effectiveness is often limited by the extremely low levels of tumor-derived DNA circulating in the blood.

9 Dec 2025

New antibody shows ability to overcome treatment resistance in blood cancers and solid tumors

In a new preclinical study, researchers from The University of Texas MD Anderson Cancer Center developed an antibody therapy called 77A that showed an ability to overcome treatment resistance in blood cancers, such as myeloma and lymphoma, as well as solid tumors.

9 Dec 2025

Australian researchers pinpoint specific genetic changes linked to severe AMD

Australian researchers have for the first time pinpointed specific genetic changes that increase the risk of severe, sight-threatening forms of age-related macular degeneration (AMD).

9 Dec 2025

Patients receiving T-cell redirecting therapies can safely be monitored at home

Patients who receive T-cell redirecting therapies are typically hospitalized for several days after treatment to watch for side effects.

9 Dec 2025

New study reveals productivity losses from substance use disorder in the U.S.

A new study shows that in 2023, substance use disorders led to nearly $93 billion in lost productivity in the United States from missed work, reduced job performance, inability to work, and lost household productivity.

9 Dec 2025

Accuracy of remote photoplethysmography drops sharply at elevated heart rates

Researchers at Bielefeld University have analyzed how reliably AI methods can detect pulse rates from simple video recordings.

9 Dec 2025

High BMI and poor physical fitness in adolescence linked to severe bacterial infections in adulthood

High BMI and poor physical fitness during later adolescence increase the risk of both contracting and dying from sepsis and other severe bacterial infections in adulthood, according to a study from the University of Gothenburg.

9 Dec 2025

Physical activity may help restore ease of movement and agility during aging

The brain-chemical surge that comes with running may bolster coordination and speed in the old and young alike, a new study of middle-aged mice shows.

9 Dec 2025

Online reference library provides a more accurate picture of drug exposure

Doctors and researchers try to understand what medications a person has taken by asking patients directly or by looking at medical records. But this information is often incomplete.

9 Dec 2025

Study reveals how brain protein KCC2 influences reward learning

A new finding from researchers at Georgetown University Medical Center shows that the learning process of associating cues with rewards can be altered by increased or decreased activity of a specific protein in the brain.

9 Dec 2025

Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced the publication of a peer reviewed study in The Journal of Cystic Fibrsosis.

9 Dec 2025

Previous
1
...
7
8
9
10
11
12
13
...
17768
Next

Medical News

Negative health impacts caused by 'forever chemicals' linked to billions in economic losses

Research ushers in a new era of hope for patients with primary immune thrombocytopenia

Disinfectant used in water treatment may impact the incidence of Legionnaire's disease

Brain function discovery helps explain why childhood adversity raises metabolic disease risk in women

Study uncovers how the body's bile acids bind to block C. diff's most dangerous toxin

Dietary restriction reprograms cancer-fighting immune cells to enhance anti-tumour immunity

TXA reduces the need for blood transfusion in patients undergoing high-risk non-cardiac surgery

New study could lead to quicker and more targeted support for vulvodyniaia

Most people wary of AI for health diagnosis but optimistic for cancer detection

Highly sensitive CRISPR-based method designed to detect low-frequency cancer mutations

New antibody shows ability to overcome treatment resistance in blood cancers and solid tumors

Australian researchers pinpoint specific genetic changes linked to severe AMD

Patients receiving T-cell redirecting therapies can safely be monitored at home

New study reveals productivity losses from substance use disorder in the U.S.

Accuracy of remote photoplethysmography drops sharply at elevated heart rates

High BMI and poor physical fitness in adolescence linked to severe bacterial infections in adulthood

Physical activity may help restore ease of movement and agility during aging

Online reference library provides a more accurate picture of drug exposure

Study reveals how brain protein KCC2 influences reward learning

Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Latest News